A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure
Braz. j. med. biol. res
; 53(11): e9728, 2020. tab, graf
Article
in English
| LILACS, Coleciona SUS
| ID: biblio-1132496
Responsible library:
BR1.1
ABSTRACT
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.
Full text:
Available
Collection:
National databases
/
Brazil
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
LILACS
/
Coleciona SUS
Main subject:
Hepatitis B virus
/
Granulocyte Colony-Stimulating Factor
/
Hepatitis B
Type of study:
Controlled clinical trial
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. med. biol. res
Year:
2020
Document type:
Article
Institution/Affiliation country:
Fifth Medical Center of Chinese PLA General Hospital/CN
/
Medical School of Chinese PLA/CN
/
Peking University International Hospital/CN